Want to join the conversation?
During 2Q16, $MYL's Generic segment third-party sales rose 4% to $2.14Bil vs. 2Q15. Specialty segment third-party net sales rose 33% vs. 2Q15, helped by higher unit volumes and realization of the benefits of customer contract negotiations related to EpiPen Auto-Injector, as well as higher sales of the Perforomist Inhalation Solution and ULTIVA.
$MON shares dip slightly; I wonder this is because of the environmental lawsuit filed by the Washington state against the production of PCBs.
My bet is that $FR will reach $32 in the short term. It’s time it broke the 52-week high and had its fair share of growth.
$WYNN got bruised up by China after its decision to cut withdrawal limit in Macau ATMs. Wynn Resorts shares went down by more than 11%! Well who could have guessed that right?